Qilu Pharmaceutical Sustainability Profile
Qilu Pharmaceutical Co., Ltd., commonly known as Qilu Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Jinan, Shandong Province, China. Founded in 1992, the company has established a strong presence in various operational regions, including Asia, Europe, and North America. Specialising in the research, development, and manufacturing of innovative medicines, Qilu Pharma focuses on areas such as oncology, cardiovascular diseases, and central nervous system disorders. Its commitment to quality and innovation has led to the successful launch of several core products, including generic and proprietary drugs that stand out for their efficacy and safety. With a robust market position, Qilu Pharmaceutical has achieved notable milestones, including numerous international certifications and partnerships, solidifying its reputation as a trusted provider in the pharmaceutical landscape.
DitchCarbon Score
How does Qilu Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Qilu Pharmaceutical's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Qilu Pharmaceutical's reported carbon emissions
Qilu Pharmaceutical, headquartered in China (CN), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges. In the absence of specific emissions data or commitments, it is important to note that Qilu Pharmaceutical's climate strategy and initiatives remain unclear. The company does not appear to inherit any emissions data or climate targets from a parent or related organization, indicating a standalone approach to its environmental impact. As the pharmaceutical industry increasingly focuses on sustainability, Qilu Pharmaceutical may need to consider developing measurable climate commitments and reduction strategies to align with industry standards and expectations.
How Carbon Intensive is Qilu Pharmaceutical's Industry?
How Carbon Intensive is Qilu Pharmaceutical's Location?
Qilu Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Qilu Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
